News & Events zu IDEXX Laboratories Inc (IDXX)IDXXIDEXX Laboratories Inc

IDEXX Launches Catalyst proBNP Test, Enhancing Cardiac Testing Capabilities

IDEXX Laboratories announced the launch of the Catalyst proBNP Test, expanding cardiac capabilities across its connected point-of-care and reference laboratory portfolio. The test measures a biomarker used to evaluate heart disease in companion animals, a condition that affects approximately 1 in 6 cats and 1 in 10 dogs. "For many veterinarians, cardiac evaluation has often involved delays, added costs, or immediate referrals," said Mike Erickson, President and Chief Executive Officer of IDEXX. "With Catalyst proBNP, veterinarians get clear, quantitative results in minutes, not days, so they can make informed decisions earlier. That changes how care is delivered and expands what's possible in everyday practice."

IDEXX Laboratories Q2 Revenue $1.22B Beats Expectations

Reports Q2 revenue $1.22B, consensus $1.2B. "Our Q2 results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization," said CEO Mike Erickson. "This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders."

Idexx Reports Q2 EPS of $4.27, Beating Consensus of $3.93

Correction: Idexx reports Q2 EPS $4.27, consensus $3.93